Dr. Pinaud's leadership philosophy inspires a culture of innovation and patient-centricity at Antharis Therapeutics, fostering a dynamic ecosystem for the creation of novel, transformative healthcare solutions.
Antharis employs a sophisticated, multi-disciplinary scientific program encompassing immunology, cellular biology, and molecular biology to drive therapeutic advancements.
Antharis Therapeutics, a biopharmaceutical company, stands at the forefront of this shift, where it develops monoclonal antibodies (mAbs) to treat cancer.
From developing transformative therapies for patients suffering from unmet medical needs to pioneering cutting-edge technologies that will improve patient outcomes and ultimately save lives, business leaders and entrepreneurs are raising the standards of healthcare through technology and innovation.
SAN DIEGO—Antharis Therapeutics Inc., a biopharmaceutical company developing a leading portfolio of oncology and neurology related immunotherapeutics, today announced the completion and integration of their acquisition of Cassyni Biopharma.
SAN DIEGO—Antharis Therapeutics, a four-year-old biopharmaceutical company developing a leading portfolio of oncology- and neurology-related immunotherapeutics, today announced the completion of its acquisition of Galileo Biotech (São Paulo, Brazil). This exciting acquisition includes X additional employees and X square feet of state-of-the-art GMP-certified laboratory space.
SAN DIEGO—Antharis Therapeutics Inc., a biopharmaceutical company developing a leading portfolio of oncology and neurology related immunotherapeutics, today announced the completion of their Series A funding.
